Biomerica, Inc.

BMRA Healthcare Medical Devices

Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025.

Revenue
−8.33%
EPS
−46,350.0%
Free cash flow
−199.3%

Quarter to August 2026, against a year earlier

1.61 0.00 0.00%
Market cap
$7.4M
P/E
0.0×
Fwd P/E
11.4×
Dividend yield
—
F-score
4/9
Altman Z
−12.45
Beneish M
−2.06
Dividend safety
n/a

Biomerica, Inc. (BMRA) EV/Sales

Alert me on EV/Sales

As of 6 November 2026, Biomerica, Inc. (BMRA) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from 0.1× (August 2024) to 30.1× (March 2020); the current reading is higher than 4% of that period. That is below the Medical Devices industry median of 2.8× and below the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2026 1.3× 23.32%
FY2025 1.0× (1.71%)
FY2024 1.0× (43.03%)
FY2023 1.8× (11.06%)
FY2022 2.0× (62.73%)
FY2021 5.5× (34.59%)
FY2020 8.4× 116.80%
FY2019 3.9× (36.33%)
FY2018 6.1× 78.85%
FY2017 3.4× 68.64%

Quarterly newest first

Period EV/Sales Change
Aug 2026 1.0× (23.44%)
May 2026 1.3× 13.34%
Feb 2026 1.1× 22.12%
Nov 2025 0.9× (9.22%)
43 more quarters

Against its own ten years

Low 0.1× High 30.1×
Ten-year median 2.6×
Current reading's percentile 4

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on BMRA